epcam immunotherapy versus specific targeted delivery of drugs
Clicks: 257
ID: 187672
2018
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Emerging Content
64.1
/100
250 views
206 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
The epithelial cell adhesion molecule (EpCAM), or CD326, was one of the first cancer associated biomarkers to be discovered. In the last forty years, this biomarker has been investigated for use in personalized cancer therapy, with the first monoclonal antibody, edrecolomab, being trialled in humans more than thirty years ago. Since then, several other monoclonal antibodies have been raised to EpCAM and tested in clinical trials. However, while monoclonal antibody therapy has been investigated against EpCAM for almost 40 years as primary or adjuvant therapy, it has not shown as much promise as initially heralded. In this review, we look at the reasons why and consider alternative targeting options, such as aptamers, to turn this almost ubiquitously expressed epithelial cancer biomarker into a viable target for future personalized therapy.
| Reference Key |
macdonald2018cancersepcam
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Joanna Macdonald;Justin Henri;Kislay Roy;Emma Hays;Michelle Bauer;Rakesh Naduvile Veedu;Normand Pouliot;Sarah Shigdar |
| Journal | The Journal of investigative dermatology |
| Year | 2018 |
| DOI |
10.3390/cancers10010019
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.